Genscript Biotech Yönetim
Yönetim kriter kontrolleri 1/4
Genscript Biotech CEO'su Weihui Shao, Jul2021 tarihinde atandı, in görev süresi 3.33 yıldır. in toplam yıllık tazminatı $ 2.48M olup, şirket hissesi ve opsiyonları dahil olmak üzere 14.3% maaş ve 85.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.034% ine doğrudan sahiptir ve bu hisseler HK$ 7.65M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 1.7 yıldır.
Anahtar bilgiler
Weihui Shao
İcra Kurulu Başkanı
US$2.5m
Toplam tazminat
| CEO maaş yüzdesi | 14.3% |
| CEO görev süresi | 3.3yrs |
| CEO sahipliği | 0.03% |
| Yönetim ortalama görev süresi | 3.6yrs |
| Yönetim Kurulu ortalama görev süresi | 1.7yrs |
Son yönetim güncellemeleri
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?
Feb 13
Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?
Jan 09CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$353k | -US$95m |
Tazminat ve Piyasa: Weihui 'nin toplam tazminatı ($USD 2.48M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 481.50K ).
Tazminat ve Kazançlar: Weihui şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.
CEO
Weihui Shao (44 yo)
3.3yrs
Görev süresi
US$2,477,000
Tazminat
Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| CEO & COO | 3.3yrs | US$2.48m | 0.034% HK$ 7.7m | |
| Co-Founder | 22.8yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | no data | Veri yok | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 1.9yrs | US$531.00k | Veri yok | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Chief Financial Officer | 3.9yrs | Veri yok | Veri yok | |
| Chief Marketing Officer for GenScript Life Science Group | no data | Veri yok | Veri yok |
3.6yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: 1548 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| Co-Founder | 9.5yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | 9.5yrs | Veri yok | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 2.5yrs | US$531.00k | Veri yok | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Member of Advisory Board | less than a year | Veri yok | Veri yok | |
| Member of Advisory Board | 5.2yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok |
1.7yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 1548 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.